طب الأمراض الجلدية

بالأسفل التجارب السريرية الحالية.

غربل قائمة الدراسات هذه بالموقع والحالة وغيرها.

1. Leveraging AI/ML Algorithms On Digital Pathology And Ex-Vivo Confocal Microscopy Imaging For Extramammary Paget’s Disease

   Rochester, Minn.

   The purpose of this study is to validate the use of ex-vivo confocal microscopy for the assessment of skin specimens derived from Mohs surgery compared to standard microscopy. To leverage deep learning models for classification, detection, and localization of tumor for extramammary Paget’s disease on ex-vivo confocal microscopy images. To leverage AI/ML to ex-vivo confocal microscopy imaging to facilitate microscopic-level imaging of extramammary Paget’s disease. To leverage deep learning models for classification, detection, and localization of tumor for extramammary Paget’s disease on frozen and permanent pathology WSIs.

2. Study Evaluating The Safety And Efficacy Of PTX-022 (QTORIN Sirolimus) In The Treatment Of Microcystic Lymphatic Malformations

   Rochester, Minn.

   The purpose of this research is to see if a new topical (applied to the skin) formulation of sirolimus, PTX-022, is safe and effective in treating people with microcystic Lymphatic Malformations (mLM). 

3. Hidradenitis Suppurativa Registry

   Rochester, Minn.

   The purpose of this study is to comprehensively characterize Hidradenitis Suppurativa (HS) from clinical and biological perspectives. Study subjects will be individuals with HS. Consented subjects will complete electronic surveys and undergo comprehensive dermatologic evaluations at designated time points. Study subjects will be asked to donate skin swabs, saliva samples, stool samples, blood samples, hair samples and/or skin specimens.

   Collected biospecimens will be stored in a local tissue bank for future study. Subjective measures will be collected to characterize the effect of disease on quality of life.

4. A Study Of Epidermolysis Bullosa Clinical Characterization And Outcomes

   Rochester, Minn.

   The aim of the Epidermolysis Bullosa Clinical Characterization and Outcomes Database (CCOD) is to collaboratively advance knowledge about epidermolysis bullosa (EB) by capturing and cataloging primary clinical data from patients with EB from multiple EB centers in North America. As EB is a rare disease, coordination and collaboration between multiple centers of excellence will expedite our understanding of disease manifestations, course, and complications, with the aim of improving future care, expanding clinical and translational research, and finding an eventual cure for individuals with EB.

5. Phase 2 Trial Of Voyager V1 In Combination With Cemiplimab In Cancer Patients

   Rochester, Minn., Scottsdale/Phoenix, Ariz., Jacksonville, Fla.

   The purpose of this study is to determine the preliminary anti-tumor activity and confirm the safety of VV1 in combination with Cemiplimab. The study will enroll patients with three distinct separate tumor cohorts. The cancers types are colorectal, head and neck carcinoma, and melanoma that are progressing on CPI treatment. Currently the study is enrolling only to the HNSCC cohort.

6. Defining The Immunologic Profile Of Sentinel Lymph Nodes And Identifying The Mechanisms Responsible For Immunosuppression

   Jacksonville, Fla., Rochester, Minn.

   The purpose of this study is to look at the effects cancer and melanoma have on the immune cells found in lymph nodes.